公开(公告)号：US20240067927A1

公开(公告)日：2024-02-29

申请号：US18492221

申请日：2023-10-23

Applicant: THE TRUSTEES OF DARTMOUTH COLLEGE

Inventor： Charles L. Sentman

IPC: C12N5/0783 ,  A61K35/17 ,  A61K39/00

CPC classification number: C12N5/0636 ,  A61K35/17 ,  A61K39/0011 ,  A61K2035/124 ,  A61K2039/5156 ,  A61K2039/585 ,  C12N2501/515 ,  C12N2511/00

Abstract: The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.

公开(公告)号：US20220025001A1

公开(公告)日：2022-01-27

申请号：US16096562

申请日：2017-04-28

Applicant: THE TRUSTEES OF DARTMOUTH COLLEGE

Inventor： Charles L. Sentman ,  Albert Gacerez

IPC: C07K14/47 ,  C07K14/725 ,  C07K14/705 ,  C07K16/28 ,  A61K35/17 ,  C12N15/86 ,  A61P35/00

Abstract: Nucleic acid constructs, vectors, and recombinant cells harboring the nucleic acid constructs or vectors are disclosed. The nucleic acid constructs include genes encoding a chimeric antigen receptor (CAR) and/or one or more transcription factors, optionally mutated. The transcription factors include those that mediate proinflammatory cytokine expression, e.g., T-bet, STAT1, or STAT4. Methods are disclosed of co-expression of the CAR and the transcription factor in a human or non-human immune cell, preferably human T cells. Also disclosed are methods for using these cells for immunotherapy, e.g., in treating cancer, infection, autoimmunity, allergy or inflammation diseases by the administration of a prophylactically or therapeutically effective amount of one or more of the nucleic acid constructs, vectors, and/or immune cells, e.g., human CAR-T cells, described herein.

公开(公告)号：US20180147240A1

公开(公告)日：2018-05-31

申请号：US15830605

申请日：2017-12-04

Applicant: THE TRUSTEES OF DARTMOUTH COLLEGE

Inventor： Tong ZHANG ,  Charles L. Sentman

IPC: A61K35/17 ,  C07K14/705 ,  C12N5/0783

Abstract: The invention is directed to T cells and other cells that express chimeric NK-p30 receptors (“chimeric NKp30 T cells”), methods of making and using chimeric NKp30 T cells, and methods of using these chimeric NKp30 T cells, isolated populations thereof, and compositions comprising the same. In another aspect, said chimeric NKp30 T cells are further designed to express a functional non-TCR receptor. The disclosure also pertains to methods of making said chimeric NKp30 T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said chimeric NKp30 T cells, populations thereof, or compositions comprising the same.

公开(公告)号：US09663763B2

公开(公告)日：2017-05-30

申请号：US15003968

申请日：2016-01-22

Applicant: THE TRUSTEES OF DARTMOUTH COLLEGE

Inventor： Charles L. Sentman

IPC: A61K39/00 ,  C12N5/0783

CPC classification number: C12N5/0636 ,  A61K2039/5156 ,  C12N2501/515

Abstract: The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.

公开(公告)号：US12065492B2

公开(公告)日：2024-08-20

申请号：US17146814

申请日：2021-01-12

Applicant: THE TRUSTEES OF DARTMOUTH COLLEGE

Inventor： Charles L. Sentman ,  Tong Zhang

IPC: A61P35/00 ,  A61K39/395 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28

CPC classification number: C07K16/2827 ,  A61K39/3955 ,  C07K14/7051 ,  C07K14/70521 ,  C07K16/2809 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/33

Abstract: Antibodies, chimeric antigen receptors, and bispecific T-cell engagers having specificity for B7-H6 and methods for using the same in the diagnosis and treatment of disorders associated with B7-H6 expression are provided.

公开(公告)号：US20240067928A1

公开(公告)日：2024-02-29

申请号：US18492310

申请日：2023-10-23

Applicant: THE TRUSTEES OF DARTMOUTH COLLEGE

Inventor： Charles L. Sentman

IPC: C12N5/0783 ,  A61K35/17 ,  A61K39/00

CPC classification number: C12N5/0636 ,  A61K35/17 ,  A61K39/0011 ,  A61K2035/124 ,  A61K2039/5156 ,  A61K2039/585 ,  C12N2501/515 ,  C12N2511/00

Abstract: The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.

公开(公告)号：US11872248B2

公开(公告)日：2024-01-16

申请号：US16882800

申请日：2020-05-26

Applicant: THE TRUSTEES OF DARTMOUTH COLLEGE

Inventor： Tong Zhang ,  Charles L. Sentman

IPC: C12N15/62 ,  A61K35/17 ,  C07K14/705 ,  C12N15/00 ,  C07K16/28 ,  C12N5/0783 ,  A61K38/00

CPC classification number: A61K35/17 ,  C07K14/70503 ,  C07K14/70521 ,  C07K14/70575 ,  C07K14/70578 ,  C07K14/70596 ,  C07K16/2803 ,  C12N5/0636 ,  C12N15/00 ,  C12N15/62 ,  A61K38/00 ,  C07K2319/00 ,  C07K2319/03 ,  C12N2800/22

Abstract: The invention is directed to T cells and other cells that express chimeric NK-p30 receptors (“chimeric NKp30 T cells”), methods of making and using chimeric NKp30 T cells, and methods of using these chimeric NKp30 T cells, isolated populations thereof, and compositions comprising the same. In another aspect, said chimeric NKp30 T cells are further designed to express a functional non-TCR receptor. The disclosure also pertains to methods of making said chimeric NKp30 T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said chimeric NKp30 T cells, populations thereof, or compositions comprising the same.

公开(公告)号：US20220333075A1

公开(公告)日：2022-10-20

申请号：US17844982

申请日：2022-06-21

Applicant: THE TRUSTEES OF DARTMOUTH COLLEGE

Inventor： Charles L. Sentman

IPC: C12N5/0783 ,  A61K35/17 ,  A61K39/00

Abstract: The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.

公开(公告)号：US10682378B2

公开(公告)日：2020-06-16

申请号：US15830605

申请日：2017-12-04

Applicant: THE TRUSTEES OF DARTMOUTH COLLEGE

Inventor： Tong Zhang ,  Charles L. Sentman

IPC: A61K35/17 ,  C07K14/705 ,  C12N5/0783 ,  A61K38/00

Abstract: The invention is directed to T cells and other cells that express chimeric NK-p30 receptors (“chimeric NKp30 T cells”), methods of making and using chimeric NKp30 T cells, and methods of using these chimeric NKp30 T cells, isolated populations thereof, and compositions comprising the same. In another aspect, said chimeric NKp30 T cells are further designed to express a functional non-TCR receptor. The disclosure also pertains to methods of making said chimeric NKp30 T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said chimeric NKp30 T cells, populations thereof, or compositions comprising the same.

公开(公告)号：US20180298336A1

公开(公告)日：2018-10-18

申请号：US15948303

申请日：2018-04-09

Applicant: THE TRUSTEES OF DARTMOUTH COLLEGE

Inventor： Charles L. Sentman

IPC: C12N5/0783 ,  A61K39/00 ,  A61K35/17 ,  A61K35/12

Abstract: The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.